Tobira Therapeutics

Tobira is focused on developing and commercializing innovative therapeutics to treat liver disease, human immunodeficiency virus, or HIV-1, fibrosis and inflammation. Its lead product candidate, cenicriviroc, or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. Tobira’s management team has extensive experience in developing and commercializing therapeutics for liver disease and HIV-1.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

ABBVIE AND CARIBOU BIOSCIENCES ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR THE RESEARCH AND DEVELOPMENT OF CAR-T CELL THERAPEUTICS

AbbVie | February 11, 2021

news image

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a ...

Read More

CELL AND GENE THERAPY

OCEAN GENOMICS AND GENINUS TEAM UP TO DEVELOP RNA-BASED BIOMARKERS AND ADVANCE RESEARCH.

Ocean Genomics, Geninus Inc | March 30, 2021

news image

Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers. The two organizations will dispatch in Korea Ocean Genomics' high level AI-based t...

Read More

MEDICAL

BIOSYNTH CARBOSYNTH FURTHER EXPANDS LIFE SCIENCES PLATFORM WITH ACQUISITION OF AALTO BIO REAGENTS

Carbosynth | May 30, 2022

news image

Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD indust...

Read More

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

news image

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More
news image

CELL AND GENE THERAPY

ABBVIE AND CARIBOU BIOSCIENCES ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR THE RESEARCH AND DEVELOPMENT OF CAR-T CELL THERAPEUTICS

AbbVie | February 11, 2021

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a ...

Read More
news image

CELL AND GENE THERAPY

OCEAN GENOMICS AND GENINUS TEAM UP TO DEVELOP RNA-BASED BIOMARKERS AND ADVANCE RESEARCH.

Ocean Genomics, Geninus Inc | March 30, 2021

Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers. The two organizations will dispatch in Korea Ocean Genomics' high level AI-based t...

Read More
news image

MEDICAL

BIOSYNTH CARBOSYNTH FURTHER EXPANDS LIFE SCIENCES PLATFORM WITH ACQUISITION OF AALTO BIO REAGENTS

Carbosynth | May 30, 2022

Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD indust...

Read More
news image

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More